Project will increase the outcome of functional screenings, expanding the use of high content screening tool based on confocal microscopy, and improve access to RNAi libraries
Xantos Biomedicine, a functional biology and drug discovery company, has been awarded a grant from the Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology (BayStMWIVT) for the expansion of its technology platform.
The overall aim of the project, which will run for two years, is to create innovative applications for the Xantos's service technology platform.
Several modules will be implemented and improved to increase the outcome of functional screenings.
In addition the project will aim at expanding the use of the Opera system (Evotec Technologies), a high content screening tool, which is based on confocal microscopy, broadening the range of assays to be performed significantly.
In addition to that further assays will be implemented to monitor the induced cellular phenotypes with complex intracellular biology.
The second goal of this project will be to improve the access to Qiagen's RNAi libraries and implementing these libraries in various novel assays and optimising this tool in combination with the traditional overexpression approach.
As announced earlier this year Xantos has signed a comarketing agreement with Qiagen.
The project and grants received will allow Xantos a highly competitive positioning of its service platform.
Stefan Wehselau, Xantos CEO, commented: "We are delighted to have approved funding under this grant programme.
"It gives us the unique opportunity to expand our established technology platform for more intensive screening projects and increase the value added for existing and new customers".
